GlaxoSmithKline
GSK
$37.43
Share price
-0.51%
Change (1 day)
-8.30%
Change (1 year)
Categories
GlaxoSmithKline (GSK) - P/B ratio
P/B ratio as of September 2023 : 5.05
According to GlaxoSmithKline's latest financial reports the company has a price-to-book ratio of 5.05.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
GlaxoSmithKline - P/B ratio (from 2001 to 2022)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2022-12-31 | 5.88 | 55.22% |
| 2021-12-31 | 3.79 | 17.06% |
| 2020-12-31 | 3.24 | -33.08% |
| 2019-12-31 | 4.83 | -76.01% |
| 2018-12-31 | 20.2 | 7.85% |
| 2017-12-31 | 18.7 | 21.55% |
| 2016-12-31 | 15.4 | 104.19% |
| 2015-12-31 | 7.53 | -44.45% |
| 2014-12-31 | 13.6 | 35.39% |
| 2013-12-31 | 10.0 | 3.22% |
| 2012-12-31 | 9.70 | 15.29% |
| 2011-12-31 | 8.41 | 24.2% |
| 2010-12-31 | 6.77 | 7.37% |
| 2009-12-31 | 6.31 | -20.44% |
| 2008-12-31 | 7.93 | 12.59% |
| 2007-12-31 | 7.04 | -12.13% |
| 2006-12-31 | 8.02 | -29.23% |
| 2005-12-31 | 11.3 | -4.19% |
| 2004-12-31 | 11.8 | 35.76% |
| 2003-12-31 | 8.71 | -31.72% |
| 2002-12-31 | 12.8 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 4.07 | -19.49% | 🇨🇭 Switzerland |
 Pfizer PFE | 1.82 | -63.91% | 🇺🇸 USA |
 Sanofi SNY | 1.74 | -65.46% | 🇫🇷 France |
 Merck MRK | 5.75 | 13.89% | 🇺🇸 USA |
 AstraZeneca AZN | 5.69 | 12.63% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | 1.51 | -70.20% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | 3.04 | -39.74% | 🇺🇸 USA |